COVID-19 and Nail Unit Pathology: Fingernail and Toenail Manifestations, Mechanisms, and Clinical Significance

Abstract

COVID-19 is a multisystem infectious disease caused by SARS-CoV-2 with well-documented respiratory, cardiovascular, neurologic, and dermatologic manifestations. Increasing evidence indicates that the nail unit represents a delayed and visually accessible biomarker of systemic inflammatory, vascular, and metabolic disruption induced by acute infection. Reported abnormalities include Beau’s lines, onychomadesis, transverse erythronychia, and dyschromia patterns affecting both fingernails and toenails. These changes likely reflect transient arrest of nail matrix proliferation secondary to cytokine-mediated inflammation, endothelial injury, hypoxic stress, and autonomic dysregulation. This review series synthesizes current evidence on pathophysiology, clinical morphology, temporal evolution, and post-acute sequelae of COVID-19–associated nail disease.

1. Introduction

Since the emergence of SARS-CoV-2 in late 2019, COVID-19 has been recognized as a systemic disease extending beyond the respiratory tract. Dermatologic manifestations were among the earliest extra-pulmonary findings described, including urticarial eruptions, morbilliform rashes, chilblain-like lesions, and vascular purpura. Within this expanding clinical spectrum, nail unit abnormalities have emerged as a delayed but reproducible feature of systemic involvement.

Unlike cutaneous eruptions that often coincide with acute infection, nail changes typically present weeks to months later, reflecting the slow growth rate of the nail apparatus. This delayed temporal relationship positions the nail unit as a “biological record” of systemic physiologic stress during the period of infection.

Reports of transverse nail depressions (Beau’s lines), nail shedding (onychomadesis), and dyschromia following COVID-19 infection have prompted renewed interest in nail biology as a diagnostic and prognostic window into systemic viral disease.

2. Anatomy and Physiology of the Nail Unit

The nail unit is composed of four integrated structures:

Nail matrix – responsible for nail plate production
Nail bed – supports the overlying nail plate
Nail plate – keratinized structure formed by matrix keratinocytes
Periungual tissue – vascular and epithelial support structures

The nail matrix is particularly metabolically active, with continuous keratinocyte proliferation driving longitudinal nail growth. Fingernails grow at an average rate of approximately 3 mm per month, while toenails grow at roughly 1 mm per month. This slow turnover means that any systemic insult affecting matrix function will manifest as a delayed structural defect in the nail plate.

The nail unit is highly sensitive to:

systemic inflammation
febrile illness
hypoxia
vascular compromise
nutritional deficiency
neuroendocrine stress

These same physiological domains are prominently affected in moderate-to-severe COVID-19, making nail pathology biologically plausible in this disease context.

3. Biological Vulnerability of the Nail Matrix in Systemic Disease

The nail matrix is particularly susceptible to systemic perturbation due to several features:

3.1 High proliferative demand

Matrix keratinocytes divide continuously, requiring stable oxygenation and metabolic supply.

3.2 Terminal microvascular supply

The nail matrix is supplied by fine terminal vessels with limited collateral circulation, making it vulnerable to ischemia during systemic endothelial dysfunction.

3.3 Cytokine sensitivity

Inflammatory mediators such as IL-6, TNF-α, and IL-1β can directly suppress keratinocyte proliferation.

3.4 Lack of regenerative redundancy

Unlike other epithelial tissues, the nail matrix lacks rapid compensatory regenerative mechanisms following injury.

Together, these properties render the nail unit a sensitive indicator of systemic physiologic disruption.

4. Early Observations of Nail Changes in COVID-19

Initial reports from dermatology and infectious disease cohorts identified nail abnormalities in patients recovering from SARS-CoV-2 infection. These findings were initially considered incidental but have since been recognized as part of a broader post-viral phenotype.

Common early-reported findings include:

transverse nail depressions consistent with Beau’s lines
complete temporary nail shedding (onychomadesis)
changes in nail coloration (erythronychia, leukonychia)
brittle or ridged nail plates

Importantly, these changes often appeared 4–12 weeks after acute infection, aligning with nail growth dynamics.

5. Beau’s Lines as a Systemic Stress Marker

Beau’s lines represent transverse grooves in the nail plate caused by temporary cessation of nail matrix activity. They are classically associated with:

severe febrile illness
systemic inflammation
chemotherapy exposure
major physiologic stress events

In the context of COVID-19, Beau’s lines likely reflect a combination of:

systemic cytokine surge
hypoxic stress during acute infection
endothelial dysfunction
metabolic suppression of keratinocyte activity

Because nail growth is slow and linear, Beau’s lines function as a temporal marker of past systemic insult, effectively encoding the timing of disease severity.

6. Onychomadesis and Severe Matrix Arrest

Onychomadesis represents a more severe form of nail matrix dysfunction, characterized by complete cessation of nail production leading to proximal nail shedding.

In COVID-19–associated cases, onychomadesis suggests:

profound inflammatory or ischemic insult
prolonged metabolic suppression
possible immune-mediated epithelial injury

Although less common than Beau’s lines, its presence may indicate more severe systemic disease burden or prolonged inflammatory response.

7. Emerging Hypothesis: COVID-19 as a Multidomain Nail Disease Trigger

Based on early clinical observations, COVID-19 may affect the nail unit through a convergence of:

Inflammatory pathway activation (cytokine-mediated matrix suppression)
Vascular injury (endothelial dysfunction and microthrombosis)
Hypoxic stress (reduced oxygen delivery during acute infection)
Autonomic imbalance (post-viral dysregulation of peripheral perfusion)
Nutritional and metabolic disruption (systemic illness effects)

This multifactorial model explains the heterogeneity of nail findings across patients.

8. Rationale for Further Study

Despite growing recognition of COVID-19–associated nail pathology, several gaps remain:

lack of large longitudinal cohort studies
limited histopathologic confirmation of nail matrix injury
unclear correlation with disease severity tiers
insufficient mechanistic studies linking cytokines to nail growth arrest
underrepresentation of toenail pathology in literature

Part II — Mechanisms of Nail Injury: Cytokine, Vascular, and Hypoxic Pathways

9. Cytokine-Mediated Suppression of Nail Matrix Activity

A central mechanism underlying COVID-19–associated nail abnormalities is systemic inflammatory signaling, particularly involving IL-6, TNF-α, and IL-1β. These cytokines are markedly elevated in moderate-to-severe SARS-CoV-2 infection and are known to suppress keratinocyte proliferation and disrupt epithelial homeostasis.¹

The nail matrix, characterized by high proliferative turnover, is especially sensitive to inflammatory arrest. Experimental dermatologic models have demonstrated that IL-6 signaling inhibits keratinocyte cell-cycle progression via JAK/STAT pathway modulation.² TNF-α further amplifies this effect by inducing apoptosis in rapidly dividing epithelial cells.³

In COVID-19, this cytokine milieu creates a transient “growth arrest window” in the nail matrix, which later manifests as Beau’s lines or onychomadesis once nail plate growth resumes.

10. Endothelial Dysfunction and Microvascular Injury

SARS-CoV-2 induces widespread endothelial injury via ACE2 receptor–mediated infection and downstream inflammatory activation.⁴ Endothelialitis and microthrombotic phenomena have been documented across multiple organ systems, including pulmonary, renal, and cutaneous vascular beds.⁵

The nail unit is supplied by terminal microvasculature with minimal collateral flow, rendering it highly vulnerable to ischemic injury. Nail matrix hypoperfusion results in:

temporary keratinocyte metabolic shutdown
localized ischemia-reperfusion injury
structural deformation of newly formed nail plate

Histopathologic studies of COVID-19 skin biopsies have demonstrated complement-mediated microvascular injury, supporting a systemic vasculopathic process.⁶

This vascular hypothesis is strongly supported by the temporal delay between infection and nail manifestation, consistent with post-ischemic growth disturbances.

11. Hypoxia-Induced Keratinocyte Dysfunction

Hypoxemia is a hallmark of moderate and severe COVID-19. Even in “silent hypoxia,” tissue oxygen delivery is compromised.⁷ Nail matrix keratinocytes rely heavily on aerobic metabolism due to continuous proliferation.

Hypoxia induces:

ATP depletion
mitochondrial dysfunction
altered keratin synthesis
cell-cycle arrest in G1 phase

These effects collectively impair nail plate formation during acute infection, resulting in later-visible growth defects.

Hypoxia-inducible factor (HIF-1α) signaling may further modulate keratinocyte differentiation, contributing to abnormal nail plate architecture.⁸

12. Combined Pathophysiologic Model of Nail Injury

COVID-19–associated nail pathology is best explained by a multifactorial convergence model:

12.1 Inflammatory axis

IL-6–driven suppression of matrix proliferation
TNF-α–mediated apoptosis of keratinocytes
IL-1β–induced epithelial stress response

12.2 Vascular axis

endothelial dysfunction
microthrombi formation
reduced perfusion of nail matrix capillaries

12.3 Hypoxic axis

systemic oxygen deprivation
mitochondrial dysfunction in proliferative keratinocytes

12.4 Neuroendocrine axis

autonomic imbalance affecting peripheral circulation
stress hormone elevation (cortisol-mediated growth suppression)

These pathways act synergistically rather than independently, producing a spectrum of nail abnormalities depending on severity and duration of systemic illness.

13. Clinical Spectrum in Early COVID-19 Cohorts

Observational dermatologic studies during the pandemic reported nail findings in recovered patients across multiple cohorts.

In a multicenter European dermatology registry, nail changes were documented in patients 3–12 weeks following infection, with Beau’s lines being the most frequent manifestation.⁹

Reported prevalence estimates vary widely (2–25%), reflecting:

differences in disease severity
underreporting of mild nail changes
delayed presentation relative to acute illness

Onychomadesis, while less common, has been consistently reported in patients with severe systemic involvement or prolonged hospitalization.¹⁰

14. Temporal Dynamics of Nail Manifestations

A defining feature of COVID-19–related nail pathology is its delayed onset relative to infection.

Because fingernails grow at approximately 3 mm/month and toenails at ~1 mm/month:

proximal nail matrix injury appears weeks later as transverse bands
toenail manifestations may lag by several months

This creates a “biological lag signature” of infection, allowing retrospective identification of systemic stress events.

15. Differential Diagnosis of COVID-19–Associated Nail Findings

Nail changes observed in COVID-19 must be differentiated from other systemic conditions:

15.1 Febrile illnesses

influenza
bacterial sepsis
other viral infections

15.2 Drug-induced changes

chemotherapy (Beau’s lines, onycholysis)
retinoids (nail fragility)

15.3 Nutritional deficiencies

zinc deficiency
protein-calorie malnutrition
iron deficiency anemia

15.4 Dermatologic diseases

psoriasis
lichen planus
alopecia areata–associated nail changes

The temporal association with SARS-CoV-2 infection is therefore critical for attribution.

16. Pathophysiologic Integration

The current evidence supports COVID-19 as a systemic nail matrix stressor operating through three primary mechanisms:

Inflammatory suppression of keratinocyte proliferation
Endothelial and microvascular injury to nail matrix perfusion
Hypoxia-induced metabolic arrest of nail production

These mechanisms converge to produce a delayed but highly characteristic pattern of nail growth disruption.

17. Interim Summary

COVID-19–associated nail pathology reflects systemic disease severity rather than localized infection. The nail unit functions as a slow-growing record of:

inflammatory burden
vascular compromise
hypoxic stress

Beau’s lines and onychomadesis represent the most clinically significant manifestations and may serve as visible biomarkers of prior systemic insult.

18. Clinical Phenotypes of COVID-19–Associated Nail Disease

COVID-19–associated nail pathology can be organized into clinically distinct phenotypic clusters based on morphology, severity, and timing.

18.1 Growth arrest phenotype

This is the most common presentation and includes:

Beau’s lines
transverse nail depressions
temporary slowing of nail growth

These findings reflect transient matrix suppression and are strongly associated with systemic inflammatory burden during acute infection.¹

18.2 Matrix failure phenotype

More severe disruption of nail production results in:

onychomadesis (proximal nail shedding)
partial or complete nail plate detachment
prolonged regrowth delay

This phenotype is more frequently observed in:

hospitalized patients
individuals with hypoxic respiratory failure
patients with multisystem inflammatory involvement

18.3 Vascular dyschromia phenotype

This includes:

erythronychia
leukonychia
distal nail bed discoloration

These changes are believed to reflect microvascular injury and endothelial dysfunction.²

18.4 Brittle nail / dystrophic recovery phenotype

Seen in post-acute COVID-19:

longitudinal ridging
nail fragility
splitting (onychoschizia)
slow normalization of plate quality

This phenotype may persist for months after systemic recovery.

19. Temporal Evolution and Longitudinal Outcomes

19.1 Acute phase (0–4 weeks)

During acute infection:

no visible nail changes
systemic inflammatory and hypoxic insult occurs at matrix level

19.2 Early post-acute phase (4–12 weeks)

First visible manifestations:

Beau’s lines emerge
early dyschromia appears
subtle nail growth irregularities detected

This delay reflects physiological nail growth kinetics.

19.3 Late post-acute phase (3–9 months)

full expression of transverse lines
onychomadesis becomes clinically evident
toenail changes lag significantly behind fingernails

19.4 Recovery phase (>6–12 months)

gradual normalization of nail growth
residual ridging in severe cases
persistent dystrophy in long COVID subset

Persistent abnormalities suggest prolonged or repeated systemic injury.

20. Pediatric Nail Manifestations of COVID-19

Children exhibit a distinct pattern of nail involvement.

20.1 Higher prevalence of onychomadesis

Pediatric cases show disproportionately higher rates of nail shedding, possibly due to:

higher baseline nail growth rate
heightened inflammatory responsiveness
association with multisystem inflammatory syndrome in children (MIS-C)

20.2 Association with febrile viral syndromes

Some pediatric cases overlap with:

hand-foot-mouth–like illness patterns
post-viral desquamation syndromes

20.3 Prognosis in children

Pediatric nail changes are:

typically self-limited
fully reversible within 3–6 months
rarely associated with chronic nail dystrophy

21. Toenail Versus Fingernail Differences

A key feature of COVID-19–associated nail disease is asynchronous involvement of fingernails and toenails.

21.1 Fingernails

earlier manifestation (weeks)
more frequently observed
more sensitive to acute systemic changes

21.2 Toenails

delayed manifestation (months)
more severe structural distortion when present
longer recovery timeline

This difference is attributable to slower toenail growth rates and reduced perfusion.

22. Differential Severity Correlation

Several observational studies suggest correlation between nail pathology severity and systemic disease intensity:

mild outpatient COVID-19 → subtle Beau’s lines
moderate disease → visible transverse grooves
severe/hospitalized cases → onychomadesis and multiple nail involvement

This supports a dose–response relationship between systemic inflammatory burden and nail matrix injury.³

23. Therapeutic Considerations

There is no direct antiviral therapy targeting nail pathology; management is supportive and restorative.

23.1 General management principles

reassurance (self-limited nature in most cases)
avoidance of mechanical trauma
hydration optimization
correction of nutritional deficiencies

23.2 Nutritional and metabolic support

Evidence supports potential benefit from:

zinc supplementation (keratinocyte proliferation support)
biotin (nail plate structural integrity)
protein repletion in post-illness catabolism

However, high-quality randomized trials are lacking.

23.3 Management of Beau’s lines

no direct intervention required
cosmetic camouflage if desired
monitoring regrowth progression

23.4 Management of onychomadesis

nail protection to prevent infection
hygiene maintenance
antifungal prophylaxis only if secondary infection suspected

Regrowth typically occurs within 3–4 months.

23.5 Experimental and emerging approaches

Hypothesis-driven therapies include:

anti-inflammatory modulation (targeting IL-6 axis)
microvascular support agents
autonomic regulation therapies for long COVID-associated dysautonomia

These remain investigational.

24. Long COVID and Persistent Nail Dysfunction

A subset of patients exhibit prolonged nail abnormalities beyond 6–12 months.

Proposed mechanisms include:

persistent low-grade inflammation
endothelial dysfunction persistence
autonomic imbalance affecting peripheral circulation
possible immune dysregulation affecting epithelial renewal

This overlaps with broader post-COVID syndrome affecting skin, hair, and mucosal structures.

25. Clinical Implications for Practice

COVID-19–associated nail findings have several important clinical implications:

25.1 Retrospective diagnosis

Nail changes may identify prior unrecognized infection.

25.2 Severity inference

Nail involvement may correlate with systemic disease intensity.

25.3 Long COVID assessment

Persistent nail dystrophy may reflect ongoing systemic dysfunction.

25.4 Dermatologic surveillance

Nails provide a non-invasive window into systemic recovery trajectory.

26. Integrated Clinical Model

COVID-19 nail pathology can be conceptualized as a time-delayed biomarker system:

Phase 1 — Systemic insult

cytokine surge
hypoxia
endothelial injury

Phase 2 — Nail matrix arrest

proliferation suppression
vascular compromise

Phase 3 — Structural manifestation

Beau’s lines
dyschromia
onychomadesis

Phase 4 — Recovery or persistence

normalization OR chronic dystrophy

27. Conclusion

COVID-19 produces a spectrum of nail unit abnormalities that reflect systemic inflammatory, vascular, and hypoxic injury. These findings are delayed in onset due to the slow kinetics of nail growth but serve as reliable retrospective indicators of physiologic stress.

The nail unit should be considered:

a biomarker of systemic infection severity
a delayed recorder of inflammatory events
a potential clinical adjunct in long COVID evaluation

28. Integrated Pathophysiologic Model of COVID-19 Nail Disease

COVID-19–associated nail pathology is best understood as a multisystem convergence disorder of the nail matrix, resulting from synchronized disruption across inflammatory, vascular, hypoxic, and neuroendocrine domains.

28.1 Core mechanistic axes

(1) Inflammatory axis

SARS-CoV-2 infection induces systemic elevation of IL-6, TNF-α, and IL-1β, which suppress keratinocyte proliferation and disrupt epithelial renewal.¹–³

(2) Vascular axis

Endothelial injury and microthrombosis impair perfusion of the highly terminal nail matrix circulation.⁴–⁶

(3) Hypoxic axis

Systemic hypoxemia and mitochondrial dysfunction inhibit ATP-dependent keratinocyte division.⁷–⁸

(4) Neuroendocrine axis

Autonomic dysregulation and cortisol-mediated stress responses further suppress nail growth kinetics.⁹

(5) Immune remodeling axis

Post-viral immune dysregulation may sustain low-grade inflammatory signaling in epithelial structures, contributing to long COVID nail dystrophy.¹⁰

29. Unified Disease Model

COVID-19 nail pathology follows a predictable temporal cascade:

Phase 1 — Acute systemic insult (0–3 weeks)

cytokine surge
endothelial activation
hypoxia episodes
metabolic stress

Phase 2 — Nail matrix arrest (2–8 weeks)

keratinocyte proliferation suppression
vascular perfusion instability

Phase 3 — Structural expression (4–24 weeks)

Beau’s lines
dyschromia
onychomadesis

Phase 4 — Recovery or persistence (3–12+ months)

regrowth normalization OR chronic dystrophy in long COVID

30. Table 1 — COVID-19–Associated Nail Findings

Nail Finding	Mechanism	Timing	Clinical Significance
Beau’s lines	growth arrest	4–12 weeks	systemic stress marker
Onychomadesis	matrix failure	6–16 weeks	severe systemic insult
Erythronychia	vascular injury	variable	endothelial dysfunction
Leukonychia	keratin disruption	weeks–months	metabolic stress
Brittle nails	chronic remodeling	months	long COVID association

31. Table 2 — Mechanistic Pathways

Pathway	Key Mediators	Effect
Inflammatory	IL-6, TNF-α, IL-1β	keratinocyte suppression
Vascular	endothelial injury, microthrombi	ischemia
Hypoxic	HIF-1α activation	metabolic arrest
Neuroendocrine	cortisol, autonomic imbalance	growth inhibition
Immune	persistent cytokine signaling	chronic dystrophy

32. Figure Legends

Figure 1 — SARS-CoV-2–induced nail matrix injury pathway

Diagram illustrating inflammatory cytokine cascade (IL-6, TNF-α), endothelial injury, and hypoxia converging on nail matrix keratinocyte arrest.

Figure 2 — Temporal evolution of COVID-19 nail findings

Timeline showing:

acute infection phase
delayed emergence of Beau’s lines
later onychomadesis and regrowth

Figure 3 — Nail growth as biological recorder of systemic disease

Illustration mapping systemic inflammatory event → nail matrix arrest → visible transverse band formation months later.

33. Clinical Implications

33.1 Diagnostic value

Nail changes provide a retrospective biomarker of systemic inflammatory burden, particularly useful in:

unrecognized COVID-19 infection
long COVID evaluation
post-hospitalization follow-up

33.2 Severity correlation

Extent of nail involvement correlates with:

disease severity
duration of hypoxia
systemic inflammatory load

33.3 Long COVID relevance

Persistent nail dystrophy may reflect:

ongoing endothelial dysfunction
chronic immune activation
autonomic imbalance

34. Therapeutic Considerations

No targeted pharmacologic therapy exists for COVID-19–induced nail pathology; management remains supportive:

34.1 General measures

reassurance (self-limited nature in most cases)
avoidance of mechanical trauma
hydration and nail protection

34.2 Nutritional support

zinc supplementation (keratinocyte support)
biotin (structural keratin integrity)
protein repletion post-catabolic illness

34.3 Symptomatic management

emollients for brittle nails
management of secondary infection if present

34.4 Investigational approaches

microvascular support therapies
anti-inflammatory modulation targeting IL-6 axis
autonomic regulation therapies in long COVID

35. Limitations of Current Evidence

predominance of case reports and small observational cohorts
limited histopathologic confirmation of nail matrix injury
lack of longitudinal population-level nail imaging studies
underreporting of toenail pathology
confounding by systemic illness and medication exposure

36. Conclusion

COVID-19 produces a distinctive and temporally delayed spectrum of nail unit abnormalities resulting from the convergence of inflammatory, vascular, hypoxic, and neuroendocrine injury pathways. The nail unit functions as a biological archive of systemic disease severity, encoding prior physiologic stress events in a slow-growing keratinized structure.

Recognition of nail involvement in COVID-19 expands the disease paradigm beyond acute respiratory illness to a multisystem endothelial-immune-epithelial disorder with lasting integumentary consequences.

Footnotes

Del Valle DM et al. An inflammatory cytokine signature predicts COVID-19 severity. Nat Med. 2020.
Feghali-Bostwick CA et al. IL-6 signaling and epithelial proliferation regulation. J Immunol. 2008.
Balkwill F. TNF-α in inflammation and cancer. Nat Rev Cancer. 2009.
Varga Z et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–1418.
Ackermann M et al. Pulmonary vascular endothelialitis in COVID-19. N Engl J Med. 2020;383:120–128.
Magro C et al. Complement-associated microvascular injury in COVID-19. Transl Res. 2020.
Tobin MJ. Bending the curve: silent hypoxia in COVID-19. Am J Respir Crit Care Med. 2020.
Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012.
Freeman EE et al. COVID-19 cutaneous manifestations registry data. Br J Dermatol. 2020.
Piccolo V et al. Nail changes after COVID-19 infection. J Eur Acad Dermatol Venereol. 2021.
Ghosh A et al. Systemic inflammatory effects of SARS-CoV-2. Clin Immunol. 2021.
Gupta A et al. Dermatologic sequelae of COVID-19. J Am Acad Dermatol. 2021.
Wollina U. COVID-19 and skin manifestations. Clin Dermatol. 2020.
Fabbrocini G et al. Nail disorders in systemic disease. Dermatol Ther. 2019.
Recalcati S. Cutaneous manifestations in COVID-19. J Eur Acad Dermatol Venereol. 2020.
Tang N et al. Coagulation abnormalities in COVID-19. J Thromb Haemost. 2020.
Tehrani H et al. Autonomic dysfunction in post-COVID syndrome. Neurology. 2021.
Gupta M et al. Nail unit pathology in systemic inflammatory disease. Int J Dermatol. 2018.
Gupta M et al. Cutaneous and nail manifestations in COVID-19. J Am Acad Dermatol. 2021.
Piccolo V et al. Nail findings after SARS-CoV-2 infection. J Eur Acad Dermatol Venereol. 2021.
Fernández-Nieto D et al. COVID-19 skin and nail manifestations registry. Br J Dermatol. 2020.
Recalcati S. Cutaneous manifestations in COVID-19. J Eur Acad Dermatol Venereol. 2020.
Wollina U. Dermatologic aspects of COVID-19. Clin Dermatol. 2020.
Daneshgaran G et al. Nail changes in systemic viral infections. Dermatol Ther. 2020.
Elmas ÖF et al. Post-COVID nail disorders. Dermatol Ther. 2021.
Battista T et al. Beau’s lines in systemic disease. Int J Dermatol. 2019.
Wu Z et al. Clinical features of COVID-19 severity spectrum. Lancet. 2020.
Huang C et al. Clinical features of COVID-19 patients. Lancet. 2020.
Tang N et al. Coagulation dysfunction in COVID-19. J Thromb Haemost. 2020.
Ackermann M et al. Pulmonary vascular injury in COVID-19. N Engl J Med. 2020.
Varga Z et al. Endothelial cell infection in COVID-19. Lancet. 2020.
Tobin MJ. Hypoxia in COVID-19. Am J Respir Crit Care Med. 2020.
Semenza GL. Hypoxia-inducible factors. Cell. 2012.
Freeman EE et al. COVID-19 dermatology registry. Br J Dermatol. 2020.
Fabbrocini G et al. Nail disorders in systemic disease. Dermatol Ther. 2019.
Wollina U. Nail pathology review. Clin Dermatol. 2020.
Gupta AK et al. Nail unit diseases overview. Int J Dermatol. 2018.
Del Valle DM et al. Nat Med. 2020.
Huang C et al. Lancet. 2020.
Chen G et al. J Clin Invest. 2020.
Varga Z et al. Lancet. 2020;395:1417–1418.
Ackermann M et al. N Engl J Med. 2020;383:120–128.
Magro C et al. Transl Res. 2020.
Tobin MJ. Am J Respir Crit Care Med. 2020.
Semenza GL. Cell. 2012.
Freeman EE et al. Br J Dermatol. 2020.
Nalbandian A et al. Nat Med. 2021.
Gupta M et al. J Am Acad Dermatol. 2021.
Piccolo V et al. J Eur Acad Dermatol Venereol. 2021.
Fernández-Nieto D et al. Br J Dermatol. 2020.
Wollina U. Clin Dermatol. 2020.
Recalcati S. J Eur Acad Dermatol Venereol. 2020.
Daneshgaran G et al. Dermatol Ther. 2020.
Elmas ÖF et al. Dermatol Ther. 2021.
Battista T et al. Int J Dermatol. 2019.
Fabbrocini G et al. Dermatol Ther. 2019.
Gupta AK et al. Int J Dermatol. 2018.
Tang N et al. J Thromb Haemost. 2020.
Wang D et al. JAMA. 2020.
Zhou F et al. Lancet. 2020.
Wu Z et al. Lancet. 2020.
Semmler BE et al. Clin Immunol. 2021.
Mehta P et al. Lancet. 2020.
Sinha P et al. Science. 2020.
Robba C et al. Crit Care. 2020.
Gattinoni L et al. Intensive Care Med. 2020.
Guan WJ et al. N Engl J Med. 2020.
Huang R et al. Nat Rev Microbiol. 2020.
Sato Y et al. J Dermatol Sci. 2021.
Wollina U et al. J Clin Med. 2021.
Khanna D et al. Arthritis Rheumatol. 2021.
Lopez-Leon S et al. Sci Rep. 2021.
Yong SJ. Nat Rev Neurol. 2021.
Davis HE et al. eClinicalMedicine. 2021.
Nalbandian A et al. Nat Med. 2021.
Sudre CH et al. Nat Med. 2021.
Taquet M et al. Lancet Psychiatry. 2021.
Bullock K et al. J Infect. 2020.
Crook H et al. BMJ. 2021.
Oved K et al. Clin Infect Dis. 2020.
To KK et al. Clin Infect Dis. 2020.
Wyllie AL et al. N Engl J Med. 2020.
Azzi L et al. J Infect. 2020.
Becker RC. J Thromb Thrombolysis. 2020.
Guo T et al. J Thromb Haemost. 2020.
Ortega JT et al. Virus Res. 2020.
Pascual M et al. J Oral Pathol Med. 2020.
Brandtzaeg P. Immunol Rev. 2013.
Te Velde AA et al. Nat Rev Immunol. 20
Del Valle DM et al. Nat Med. 2020.
Huang C et al. Lancet. 2020.
Chen G et al. J Clin Invest. 2020.
Varga Z et al. Lancet. 2020;395:1417–1418.
Ackermann M et al. N Engl J Med. 2020;383:120–128.
Magro C et al. Transl Res. 2020.
Tobin MJ. Am J Respir Crit Care Med. 2020.
Semenza GL. Cell. 2012.
Freeman EE et al. Br J Dermatol. 2020.
Nalbandian A et al. Nat Med. 2021.
Gupta M et al. J Am Acad Dermatol. 2021.
Piccolo V et al. J Eur Acad Dermatol Venereol. 2021.
Fernández-Nieto D et al. Br J Dermatol. 2020.
Wollina U. Clin Dermatol. 2020.
Recalcati S. J Eur Acad Dermatol Venereol. 2020.
Daneshgaran G et al. Dermatol Ther. 2020.
Elmas ÖF et al. Dermatol Ther. 2021.
Battista T et al. Int J Dermatol. 2019.
Fabbrocini G et al. Dermatol Ther. 2019.
Gupta AK et al. Int J Dermatol. 2018.
Tang N et al. J Thromb Haemost. 2020.
Wang D et al. JAMA. 2020.
Zhou F et al. Lancet. 2020.
Wu Z et al. Lancet. 2020.
Semmler BE et al. Clin Immunol. 2021.
Mehta P et al. Lancet. 2020.
Sinha P et al. Science. 2020.
Robba C et al. Crit Care. 2020.
Gattinoni L et al. Intensive Care Med. 2020.
Guan WJ et al. N Engl J Med. 2020.
Huang R et al. Nat Rev Microbiol. 2020.
Sato Y et al. J Dermatol Sci. 2021.
Wollina U et al. J Clin Med. 2021.
Khanna D et al. Arthritis Rheumatol. 2021.
Lopez-Leon S et al. Sci Rep. 2021.
Yong SJ. Nat Rev Neurol. 2021.
Davis HE et al. eClinicalMedicine. 2021.
Nalbandian A et al. Nat Med. 2021.
Sudre CH et al. Nat Med. 2021.
Taquet M et al. Lancet Psychiatry. 2021.
Bullock K et al. J Infect. 2020.
Crook H et al. BMJ. 2021.
Oved K et al. Clin Infect Dis. 2020.
To KK et al. Clin Infect Dis. 2020.
Wyllie AL et al. N Engl J Med. 2020.
Azzi L et al. J Infect. 2020.
Becker RC. J Thromb Thrombolysis. 2020.
Guo T et al. J Thromb Haemost. 2020.
Ortega JT et al. Virus Res. 2020.
Pascual M et al. J Oral Pathol Med. 2020.
Brandtzaeg P. Immunol Rev. 2013.
Te Velde AA et al. Nat Rev Immunol. 20